Benzyl Benzoate

Summary

Benzyl Benzoate (CHEMBL1239) is an approved small-molecule scabicide (ATC P03AX01); indicated across 1 condition including parasitic infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P03AX01
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 212.24 Da · C14H12O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1239
Name	Benzyl Benzoate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2345
ChEBI	CHEBI:41237
ATC	P03AX01
Molecular formula	C14H12O2
Molecular weight	212.24
InChIKey	SESFRYSPDFLNCH-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)COC(=O)C2=CC=CC=C2

IUPAC name: benzyl benzoate

ChEBI definition: A benzoate ester obtained by the formal condensation of benzoic acid with benzyl alcohol. It has been isolated from the plant species of the genus Polyalthia.

Pharmacological roles (ChEBI): scabicide, acaricide.

Other ChEBI roles (chemical / environmental): plant metabolite.

Also known as: Ascabiol, Benzoic acid, benzyl ester, Benzyl benzoate, Benzylis benzoas, FEMA NO. 2138, Mange treatment, NSC-8081, Scabiozon, Scabanca, Venzonate, Vanzoate

Patent coverage: 49,195 distinct patent families (162,300 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Ferritin light chain, Histone-lysine N-methyltransferase 2A, Beta-lactamase, Sodium-dependent noradrenaline transporter, Sodium-dependent dopamine transporter, Hormone-sensitive lipase.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P15304	5.96	IC50	1100	nM	CHEMBL_ACT_2370403
SLC6A3	5.06	AC50	8730	nM	CHEMBL_ACT_25124907
SLC6A2	5	AC50	9940	nM	CHEMBL_ACT_25145948

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
parasitic infectious disease	4	MONDO:0005135	EFO:0001067

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04205669	PHASE4	COMPLETED	Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).